CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Nuo Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Nuo Therapeutics Inc
8285 EL RIO, SUITE 150
Phone: (832) 236-9060p:832 236-9060 HOUSTON, TX  77054  United States Ticker: AURXAURX
Business Summary
Nuo Therapeutics, Inc. is a regenerative therapies company. The Company is focused on developing and marketing products for chronic wound care primarily within the United States. The Company commercializes cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. Its flagship product, Aurix, is a biodynamic hematogel that uses a patient’s own platelets and plasma as a catalyst for healing. The Company’s commercial offering consists of point of care technology for the safe and effective separation of autologous blood to produce a platelet-based therapy for the chronic wound care market. This offering is known as Aurix (the Aurix System), which produces a platelet rich plasma (PRP) gel at the point of care using the patient’s own platelets and plasma sourced from a small draw of peripheral blood. Aurix comprises a natural, endogenous complement of protein and non-protein signal molecules that contribute to effective healing.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYesYesYesYes

Industries
SIC Code Description
3841 Surgical and medical instruments and apparatus
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer, Chief Financial Officer, Director David E.Jorden 60 7/1/2016 9/19/2008
Chief Operating Officer, Chief Scientific Officer Peter A.Clausen 57 1/1/2022 4/1/2014
Independent Director Paul D.Mintz 74 4/7/2017 4/7/2017
Independent Director Scott M.Pittman 64 5/5/2016 5/5/2016
Independent Director C. EricWinzer 66 1/30/2009 1/30/2009

Subsidiaries
Business Name Address City State/Province Country
Aldagen Inc 2810 Meridian Parkway, Durham NC United States

Business Names
Business Name
Aldagen, Inc.
AURX
NUOTQ

General Information
Number of Employees: 7 (As of 12/31/2018)
Outstanding Shares: 44,241,516 (As of 4/15/2024)
Shareholders: 800
Stock Exchange: OTC
Federal Tax Id: 233011702
Fax Number: (240) 499-2690


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 25, 2024